^
    Back
    Association details:
    Biomarker:CD20 negative
    Cancer:Diffuse Large B Cell Lymphoma
    Regimen:EPOCH (cyclophosphamide + doxorubicin hydrochloride + etoposide IV + + vincristine)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    University of Oxford
    Title:

    Case report of primary CD20 negative diffuse large B-cell lymphoma

    Published date:
    11/25/2021
    Excerpt:
    A 33-year-old male...diagnosis of primary CD20 negative DLBCL, which is a high-grade lymphoma, we started him on infusion chemotherapy regimen i.e. EPOCH (Etoposide, Prednisolone, Doxorubicin, vincristine along with bolus of cyclophosphamide). His follow-up interim scan done after four cycles of EPOCH did not show any change in the disease status (treatment failure)...Our patient did not respond to EPOCH chemotherapy regimen.
    DOI:
    https://doi.org/10.1093/omcr/omab114